Aposense

  • Home
  • About Us
    • Overview
    • Scientific president
    • Team
    • Board of directors
    • Intellectual property
  • Our Technology
  • SirVir
    • Aposense subsidiary in the field of respiratory viral infections
  • ATT-11T: Anti cancer pro-drug
    • On June 1st 2020 Aposense signed an agreement to license out the ATT-11T to Processa Pharmaceuticals
  • News
  • Contact Us


SirVir announces COVID-19 accelerated development program

February 5 2020

SirVir, an Aposense subsidiary, announces the accelerated development of a treatment for the COVID-19

News
Read More
Aposense

Contact Us

Telephone: + 972.73.239.7600
Fax: +972.3.921.57.14
E-mail: info@aposense.com

Careers

Latest news

  • Prof. Roger Kornberg mentions SirVir’s breakthrough results and applicability of the platform in an interview for Ynet.

    7 Jan 2021

  • Aposense enters into an out-licensing agreement with Processa Pharmaceuticals

    1 Jun 2020

  • SirVir obtained positive results in pre-clinical experiment against COVID-19

    26 Apr 2020

Aposense © 2021. Privacy Policy
  • Home
  • About Us
    ▼
    • Overview
    • Scientific president
    • Team
    • Board of directors
    • Intellectual property
  • Our Technology
  • SirVir
    ▼
    • Aposense subsidiary in the field of respiratory viral infections
  • ATT-11T: Anti cancer pro-drug
    ▼
    • On June 1st 2020 Aposense signed an agreement to license out the ATT-11T to Processa Pharmaceuticals
  • News
  • Contact Us
Skip to content
Open toolbar

Accessibility Tools

  • Increase Text
  • Decrease Text
  • Grayscale
  • High Contrast
  • Negative Contrast
  • Light Background
  • Links Underline
  • Readable Font
  • Reset